Novavax and Serum Institute of India Collaborate to Develop and Commercialize Vaccines for Malaria

 Novavax and Serum Institute of India Collaborate to Develop and Commercialize Vaccines for Malaria

Novavax and Serum Institute of India Collaborate to Develop and Commercialize Vaccines for Malaria

Shots:

  • Novavax to receive royalties on the sales of vaccines and will provide its Matrix-M vaccine adjuvant to SII. Additionally, the company gets right to commercialize SII-manufactured vaccine in high-income countries, primarily in the travelers and military vaccine markets
  • SII gets access to utilize Novavax’s Matrix-M vaccine adjuvant with its malaria vaccine candidate (R21 malaria vaccine), licensed from the Jenner Institute at Oxford University in 2017
  • R21 malaria vaccine along with Matrix-M is currently being evaluated in P-IIb study to target Plasmodium falciparum-induced malaria with its expected results to be reported in Q2’20

Click here ­to­ read full press release/ article | Ref: Novavax  | Image: Fierce Pharma

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post